Rxsight Inc (RXST)

Currency in USD
7.55
-0.10(-1.31%)
Closed·
After Hours
7.83+0.28(+3.71%)
·
RXST Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
RXST is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.527.79
52 wk Range
6.3258.23
Key Statistics
Prev. Close
7.65
Open
7.61
Day's Range
7.52-7.79
52 wk Range
6.32-58.23
Volume
858.37K
Average Volume (3m)
1.28M
1-Year Change
-84.22%
Book Value / Share
6.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RXST Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.22
Upside
+61.88%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Rxsight Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Rxsight Inc Company Profile

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Rxsight Inc Earnings Call Summary for Q1/2025

  • RxSight Q1 2025 EPS of -$0.03 beat forecast of -$0.20; revenue of $37.9M up 28% YoY but missed estimates
  • Stock rose 6.67% post-earnings; company maintains strong financial health with more cash than debt
  • Gross margin improved to 74.8%; cash and investments increased to $229.3M
  • Full-year 2025 revenue guidance: $160M-$175M, projecting 14-25% growth; expects LAL volume recovery in H2
  • CEO highlighted structural shift in premium IOL market, emphasizing LAL technology advantages and product pipeline
Last Updated: 07/05/2025, 22:48
Read Full Transcript

Compare RXST to Peers and Sector

Metrics to compare
RXST
Peers
Sector
Relationship
P/E Ratio
−11.6x−2.9x−0.5x
PEG Ratio
−0.25−0.080.00
Price/Book
1.1x2.3x2.6x
Price / LTM Sales
2.1x3.8x3.3x
Upside (Analyst Target)
17.6%24.3%43.5%
Fair Value Upside
Unlock6.6%6.9%Unlock

Analyst Ratings

1 Buy
8 Hold
2 Sell
Ratings:
11 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 12.22
(+61.88% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.20 / -0.20
Revenue / Forecast
37.90M / 39.09M
EPS Revisions
Last 90 days

RXST Income Statement

People Also Watch

16.26
SRPT
-2.93%
25.21
CNC
-2.63%
38.44
BMNR
+15.42%
7.740
CAPR
+0.91%
5.50
REPL
-12.97%

FAQ

What Stock Exchange Does Rxsight Trade On?

Rxsight is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Rxsight?

The stock symbol for Rxsight is "RXST."

What Is the Rxsight Market Cap?

As of today, Rxsight market cap is 306.40M.

What Is Rxsight's Earnings Per Share (TTM)?

The Rxsight EPS (TTM) is -0.67.

When Is the Next Rxsight Earnings Date?

Rxsight will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is RXST a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Rxsight Stock Split?

Rxsight has split 0 times.

How Many Employees Does Rxsight Have?

Rxsight has 498 employees.

What is the current trading status of Rxsight (RXST)?

As of 07 Aug 2025, Rxsight (RXST) is trading at a price of 7.55, with a previous close of 7.65. The stock has fluctuated within a day range of 7.52 to 7.79, while its 52-week range spans from 6.32 to 58.23.

What Is Rxsight (RXST) Price Target According to Analysts?

The average 12-month price target for Rxsight is USD12.22222, with a high estimate of USD22 and a low estimate of USD9. 1 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Neutral. The stock has an +61.88% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.